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Abstract
Intravenous administration of immunoglobulin is used
for the treatment ofmany conditions, including primary
immunodeficiency states. autoimmune disorders.
giomerulonephritides and polyneuropathy ‘-‘ Acute
renal failure induced by intravenous immunoglobulin is
a known but rare adverse reaction. We have a patient
who was treated with IVIG for inflammatory polyneu
ropathy Intravenous immunoglobulin therapyO. 5g/kg/
d was given for 4 days. Three days after completion
of IVIG therapy patient developed decreased urine
output. His serum creatinine increased from baseline
of 1.3 to 7mg/dL. Even though/V/C was discontinued.
patient required hemodialysis. This case illustrated
that IVIG can cause acute oliguric renal failure which
is reversible after withdrawal of the drug. Risk factors
include pretreatment renalimpairment. diabetes mel
litus, high concentration of sucrose or glucose in IVIG
preparation and older age. Awareness of this serious
side effects and recognition of predisposing factors
provide means of avoiding a known life threatening
complication of/V/C therapy
Case report
A 76-year-old Chinese male with a history of inflam
matory polyneuropathy was admitted for acute renal
failure following treatment with IVIG. The patient has
been well until one year earlier when he developed
progressive lower extremities weakness. He was seen
by a neurologist and inflammatory polyneuropathy
was diagnosed based on a nerve conduction study.
The patient was admitted by his neurologist for IVIG
injection (Panglobulin, ZLB). He was hospitalized for
4 days and received IVIG treatment with the dose of
2 mg/kg for maximal rate of 100 mI/h. The admit
ting serum creatinine was 1.3mg/di. On the third day
of the treatment with IVIG. creatinine increased to
1.Smg/di. The patient was discharged 3 days before
this admission. For two days prior to the second
admission, the patient noted decreased urine output.
The patient also developed fatigue with anorexia.
Because of those symptoms, he was evaluated in the
emergency room and was found to have acute renal
failure with a serum creatinine of 7.Omg/dL and BUN
of 71 mg/dL. Aside from fatique. he denies having
nausea, pruritus or shortness of breath. He denies the
use of over-the-counter pain medications. The patient
has a history of diabetes type II for more than 15 years.
hypertension, chronic obstructive pulmonary disease
and coronary artery disease.
The results of an extended physical examination
was significant for elevated blood pressure of 171/71
mml-lg: lung examinations were normal. Heart exami
nation revealed normal sinus rhythm. no pericardial
rub, no murmur audible. The patient had no asterixes.
The neurological examination was remarkable for
muscle strength grade 5/5 in the upper extremities,
4/5 ofboth iliopsoas, 2/5 of gastrocnemius and tibialis
anterior muscles, mild atrophy ofcalfand hyporeflexia
of both lower extremities, negative Babinski’s sign
bilaterally.
A renal ultrasonographv ‘as performed which
showed right kidney 10.1 cm in diameter, left kidney
11.2 cm with 1 .3cm cyst at lower pole of left kidney
without hydronephrosis.
Foley’s catheter was inserted in the emergency room
which yielded only l0ml of urine. Furosemide 50mg
was given intravenously without response, followed
by continuous intravenous infusion drip with the
rate of 30mg/hr without response. The patient had
peak serum creatinine of 8.8mg/dI. On the third day
of the admission, acute hemodialysis was performed
because of anuria and uremia. Shortly after dialysis.
on the fourth day of hospitalization, his urine output
increased and eventually became polyuric. Serum
creatinine continued to improve throughout the
hospitalization. The patient was discharged on the
seventh day of hospitalization with serum creatinine
of 2.4mg/di. He was followed by the nephrologist as
an out-patient with clinical improvement of serum
creatinine back to baseline.
Discussion
IVIG induced acute renal failure was first described in
1987.” Inreview ofcase series, most ofthepatients had
a small andtransientelevation in the plasmacreatinine
concentration that may reflect a reduction in creatinine
secretion rather than the fall in glomerular filtration
rate.9 In the group of patients who developed acute
renal failure, 48 7c were more than 65 years old and
in 57% of them there was preexisting renal disease
such as diabetes and renal insufficiency.”46’9
Between 1985-1998, the Federal Drug Admin
istration received a total of 120 reports of adverse
renal events (acute renal failure and renal insuf
ficiency) associated with high dose IVIG therapy.
On review of these reports 90% of the patient had
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received sucrose containing IVIG: Sandoglobuim
and Panglobulin (combined responsible for 69% ci
all cased in the United States), Gammar-P.l.V. and
Gammar-l.V.b.(were responsible for 22 percent of
the cases) Fifty — nine percent had diabetes mellitus
and 26% had pretreatment renal impairment. All renal
adverse events occurred in the first 7 days following
the administration ofiViG therapy. Di In our case, the
temporal relationship between acute renal failure and
IVIG administration was consistent with that seen in
lrevious reports. there was no other apparent cause
for the acute renal failure.
The mechanism ofIVlG induced acute renal failure
was previously thought to be due to aggregated irn
munoglobulin complex. However, as series of typical
histological findings of renal biopsy in these patient
showed vacuolization and swelling of tubular and
glomerular cells has drawn attention to the high con
centration of carbohydrate additive in IVJG. Sucrose
is the main carbohydrate which is added to WIG as a
stabilizing agent. Uptake of filtered sucrose by proxi
mal tubular cells leads to osmotic water entry and eel!
swelling which is called “ osmotic nephrosis’1
Osmotic injury by sucrose is the leading hypothesis
for IVIG induced acute renal failure, however, there
are some arguments against this mechanism since the
patient do not present with true hypertonic syndrome.
The hypertonic IVIG solutions are quickly diluted
in blood. Furthermore, if it was the tonicity causing
tubular damage, one would expect to see more severe
lesions in the distal proximal tubule where the osmo
lality due to reabsorption of water and sodium is the
highest. But histologic examination indicated that
F proximal segment of the proximal tubule was the part
with the most damage. Also, based on animal stud
ies, it is unlikely that carbohydrate alone can cause
severe impairment of kidney function. Some under
lying renal disease or drug affecting renal function
or hemodynamics seem to be important contributing
factors for the development of acute renal failure.
Healthy rats treated with high dose mannitol alone did
not developed renal failure. Only after concomitant
administration of cyclosporin and IV mannitol did the
animal develop marked deterioration in renal function
and osmotic nephrosis on histology. Asimilarobserva
tion with severe oligurie acute renal failure was noted
in a human kidney graft recipient on cyclosporin. in
whom a large amount of mannitol had been injected
intravenously. Lately, non-sucrose containing IVIG
preparation have been used successfully in patients
with previous history of IVIG-associated acute renal
failure.
Acute renal failure occurred in most cases during
first exposure to IVIG. The clinical manifestation
varies from asvmptomatic rise in plasma creatinine
concentration to anuric acute renal failure requiring
hemodialysis. Risk factors for IVIG induced acute
renal failure include including age more than 65, those
with preexisting renal insufficiency, diabetes mellitus,
volume depletion or those who receiving nephrotox ic
drug. Spontaneous resolution typically occurs within
4-S (lays after discontinuation of IVIG. Identification
of patients who are at risk for developing acute renal
hulure caused by IVIG.
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